MD

Medartis Holding AGOOTC MDRSF Stock Report

Last reporting period 30 Jun, 2024

Updated 29 Oct, 2024

Last price

Market cap $B

0.87

Micro

Exchange

OOTC - OTC

MDRSF Stock Analysis

MD

Uncovered

Medartis Holding AG is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

38/100

Low score

Market cap $B

0.87

Dividend yield

Shares outstanding

11.857 B

Medartis Holding AG engages in the development, manufacture, and sale of medical devices for surgical fixation of bone fractures. The company is headquartered in Basel, Basel-Stadt and currently employs 866 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.

View Section: Eyestock Rating